A carregar...
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients
AIMS: Sifalimumab, a human immunoglobulin (Ig) G1 monoclonal antibody against INF‐alpha, is being studied as a treatment for systemic lupus erythematosus (SLE). This analysis characterized population pharmacokinetics (PK) of sifalimumab following repeat fixed dose and evaluated the utility of fixed...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4834601/ https://ncbi.nlm.nih.gov/pubmed/26659791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12864 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|